Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - rizatriptan benzoate, quantity: 7.265 mg (equivalent: rizatriptan, qty 5 mg) - tablet, orally disintegrating - excipient ingredients: mannitol; microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; crospovidone; aspartame; calcium silicate; flavour - rizatriptan odt gh is indicated for the acute treatment of migraine attacks with or without aura.

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - rizatriptan benzoate, quantity: 14.53 mg (equivalent: rizatriptan, qty 10 mg) - tablet, orally disintegrating - excipient ingredients: crospovidone; aspartame; colloidal anhydrous silica; mannitol; microcrystalline cellulose; magnesium stearate; calcium silicate; flavour - rizatriptan odt gh is indicated for the acute treatment of migraine attacks with or without aura.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rizatriptan benzoate, quantity: 14.53 mg (equivalent: rizatriptan, qty 10 mg) - tablet, orally disintegrating - excipient ingredients: aspartame; crospovidone; calcium silicate; colloidal anhydrous silica; magnesium stearate; mannitol; microcrystalline cellulose; flavour - rizatriptan odt is indicated for the acute treatment of migraine attacks with or without aura.

United States - English - NLM (National Library of Medicine)

jubilant cadista pharmaceuticals inc. - rizatriptan benzoate (unii: wr978s7qhh) (rizatriptan - unii:51086hbw8g) - rizatriptan 5 mg - rizatriptan benzoate tablets are indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old. limitations of use - rizatriptan benzoate tablets should only be used where a clear diagnosis of migraine has been established. if a patient has no response for the first migraine attack treated with rizatriptan benzoate tablets, the diagnosis of migraine should be reconsidered before rizatriptan benzoate tablets are administered to treat any subsequent attacks.  - rizatriptan benzoate tablets are not indicated for use in the management of hemiplegic or basilar migraine [see contraindications (4)] .  - rizatriptan benzoate tablets are not indicated for the prevention of migraine attacks.  - safety and effectiveness of rizatriptan benzoate tablets have not been established for cluster headache. rizatriptan benzoate is contraindicated in patients with: - ischemic coronary artery disease (angina pectoris, history of myocardial infarction, or documented silent

Australia - English - Department of Health (Therapeutic Goods Administration)

medsurge pharma pty ltd - rizatriptan benzoate, quantity: 14.53 mg (equivalent: rizatriptan, qty 10 mg) - tablet, orally disintegrating - excipient ingredients: crospovidone; aspartame; colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; calcium silicate; mannitol; flavour - rizatriptan-au is indicated for the acute treatment of migraine attacks with or without aura.

Australia - English - Department of Health (Therapeutic Goods Administration)

medsurge pharma pty ltd - rizatriptan benzoate, quantity: 7.265 mg (equivalent: rizatriptan, qty 5 mg) - tablet, orally disintegrating - excipient ingredients: calcium silicate; magnesium stearate; aspartame; mannitol; crospovidone; microcrystalline cellulose; colloidal anhydrous silica; flavour - rizatriptan-au is indicated for the acute treatment of migraine attacks with or without aura.

United States - English - NLM (National Library of Medicine)

panacea biotec limited - rizatriptan benzoate (unii: wr978s7qhh) (rizatriptan - unii:51086hbw8g) - rizatriptan 5 mg - rizatriptan benzoate orally disintegrating tablets are indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old. limitations of use - rizatriptan benzoate orally disintegrating tablets should only be used where a clear diagnosis of migraine has been established. if a patient has no response for the first migraine attack treated with rizatriptan benzoate orally disintegrating tablets, usp, the diagnosis of migraine should be reconsidered before rizatriptan benzoate orally disintegrating tablets, usp are administered to treat any subsequent attacks. - rizatriptan benzoate orally disintegrating tablets are not indicated for use in the management of hemiplegic or basilar migraine [see  contraindications (4)] . - rizatriptan benzoate orally disintegrating tablets are not indicated for the prevention of migraine attacks. - safety and effectiv

United States - English - NLM (National Library of Medicine)

bionpharma inc., - rizatriptan benzoate (unii: wr978s7qhh) (rizatriptan - unii:51086hbw8g) - rizatriptan 5 mg - rizatriptan benzoate orally disintegrating tablets are indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old. limitations of use - rizatriptan benzoate orally disintegrating tablets should only be used where a clear diagnosis of migraine has been established. if a patient has no response for the first migraine attack treated with rizatriptan benzoate orally disintegrating tablets, usp, the diagnosis of migraine should be reconsidered before rizatriptan benzoate orally disintegrating tablets, usp are administered to treat any subsequent attacks. - rizatriptan benzoate orally disintegrating tablets are not indicated for use in the management of hemiplegic or basilar migraine [see  contraindications (4)] . - rizatriptan benzoate orally disintegrating tablets are not indicated for the prevention of migraine attacks. - safety and effectiv

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - rizatriptan benzoate, quantity: 14.53 mg (equivalent: rizatriptan, qty 10 mg) - wafer - excipient ingredients: glycine; mannitol; gelatin; aspartame; flavour - rizatriptan wafers-10mg is indicated for the acute treatment of migraine attacks with or without aura.

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - rizatriptan benzoate (unii: wr978s7qhh) (rizatriptan - unii:51086hbw8g) - rizatriptan 5 mg - rizatriptan benzoate orally disintegrating tablets are indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old. limitations of use: rizatriptan benzoate orally disintegrating tablets are contraindicated in patients with: there are no adequate and well-controlled studies in pregnant women. rizatriptan benzoate should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. in a general reproductive study in rats, birth weights and pre- and post-weaning weight gain were reduced in the offspring of females treated prior to and during mating and throughout gestation and lactation with doses of 10 and 100 mg/kg/day. in a pre- and post-natal developmental toxicity study in rats, an increase in mortality of the offspring at birth and for the first 3 days after birth, a decrease in pre- and post-weaning weight gain, and decreased performance in a passive avoidance test (which indicates a decrease in learning capa